Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes.
Of recent, clinical interest have been two related human G-protein coupled receptors: formylpeptide receptor (FPR), linked to antibacterial inflammation and malignant glioma cell metastasis; and FPR like-1 (FPRL1), linked to chronic inflammation in systemic amyloidosis, Alzheimer's disease, and prion diseases. In association with the National Institutes of Health (NIH) Molecular Library Screening Network, we implemented a flow-cytometry-based high-throughput screening (HTS) approach for identifying selective small molecule FPR and FPRL1 ligands. The screening assay measured the ability of test compounds to competitively displace a high-affinity, fluorescein- labeled peptide ligand from FPR, FPRL1, or both. U937 cells expressing FPR and rat basophil leukemia (RBL) cells expressing FPRL1 were tested together in a "duplex" format. The U937 cells were color coded with red-fluorescent dye allowing their distinction during analysis. Compounds, cells, and fluorescent ligand were sequentially combined (no wash) in 15 microl assay volumes in 384-well plates. Throughput averaged approximately 11 min per plate to analyze approximately 4,000 cells ( approximately 2,000/receptor) in a 2 microl aspirate from each well. In primary single concentration HTS of 24,304 NIH Small Molecule Repository compounds, 253 resulted in inhibition >30% (181 for FPR, 72 for FPRL1) of which 40 had selective binding inhibition constants (K(i)) < or = 4 microM (34 for FPR and 6 for FPRL1). An additional 1,446 candidate compounds were selected by structure-activity-relationship analysis of the hits and screened to identify novel ligands for FPR (3570-0208, K(i) = 95 +/- 10 nM) and FPRL1 (BB-V-115, K(i) = 270 +/- 51 nM). Each was a selective antagonist in calcium response assays and the most potent small molecule antagonist reported for its respective receptor to date. The duplex assay format reduced assay time, minimized reagent requirements, and provided selectivity information at every screening stage, thus proving to be an efficient means to screen for selective receptor ligand probes.
Young
Susan M
SM
University of New Mexico, Albuquerque, 87131, USA.
Bologa
Cristian M
CM
Fara
Dan
D
Bryant
Bj K
BK
Strouse
Juan Jacob
JJ
Arterburn
Jeffrey B
JB
Ye
Richard D
RD
Oprea
Tudor I
TI
Prossnitz
Eric R
ER
Sklar
Larry A
LA
Edwards
Bruce S
BS
D000818:Animals; D002478:Cells, Cultured; D002630:Chemotactic Factors / Q000378:metabolism; D005434:Flow Cytometry / Q000379:methods*; D005456:Fluorescent Dyes; D006801:Humans; D008024:Ligands; D015335:Molecular Probes / Q000032:analysis; D051381:Rats; D044042:Receptors, Formyl Peptide / Q000037:antagonists & inhibitors* / Q000378:metabolism; D044067:Receptors, Lipoxin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012680:Sensitivity and Specificity; D020298:U937 Cells
D002630:Chemotactic Factors; C105101:FPR2 protein, human; D005456:Fluorescent Dyes; D008024:Ligands; D015335:Molecular Probes; D044042:Receptors, Formyl Peptide; D044067:Receptors, Lipoxin
Blood. 2003 Feb 15;101(4):1572-81
12393391
J Exp Med. 1995 Jul 1;182(1):207-17
7540650
J Exp Med. 1982 Jan 1;155(1):264-75
6274994
J Biol Chem. 1992 Apr 15;267(11):7637-43
1373134
J Mol Cell Cardiol. 1997 Mar;29(3):881-94
9152849
Bioorg Med Chem Lett. 2006 Jul 15;16(14):3713-8
16697190
Cytokine Growth Factor Rev. 2001 Mar;12(1):91-105
11312121
J Natl Cancer Inst. 2005 Jun 1;97(11):823-35
15928303
J Exp Med. 2000 Oct 2;192(7):1069-74
11015447
Annu Rev Immunol. 1991;9:617-48
1910690
J Exp Med. 1999 Feb 15;189(4):657-62
9989980
Clin Immunol. 2000 Sep;96(3):236-42
10964542
J Immunol. 2003 Aug 15;171(4):2050-6
12902510
J Immunol. 1975 Jun;114(6):1831-7
165239
Biochem Biophys Res Commun. 1992 Apr 30;184(2):582-9
1374236
Pharmacol Ther. 1997;74(1):73-102
9336017
Mol Cell. 2000 May;5(5):831-40
10882119
J Neuroimmunol. 1995 Aug;61(1):71-8
7560015
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448-53
9600986
J Immunol. 1999 May 15;162(10):5924-30
10229829
Mol Cancer Ther. 2007 Oct;6(10):2618-25
17938258
Curr Opin Hematol. 1999 Jan;6(1):15-24
9915549
Mol Pharmacol. 2007 Oct;72(4):976-83
17652444
Genomics. 1992 Jun;13(2):437-40
1612600
J Neuroimmunol. 2000 Nov 1;111(1-2):102-8
11063827
Cytometry. 1998 Oct 1;33(2):234-43
9773885
J Exp Med. 1999 Jan 18;189(2):395-402
9892621
Cytometry A. 2003 May;53(1):55-65
12701132
J Exp Med. 2000 Apr 3;191(7):1197-208
10748237
J Neurooncol. 2008 Jan;86(1):47-53
17611713
J Exp Med. 1998 Apr 20;187(8):1285-94
9547339
Nature. 1996 Mar 28;380(6572):345-7
8598929
Cytometry. 2001 May 1;44(1):83-90
11309812
J Immunol. 2001 Feb 1;166(3):1448-51
11160182
J Recept Res. 1988;8(1-4):533-46
3385692
J Biomol Screen. 2005 Jun;10(4):374-82
15964939
J Immunol. 1995 Oct 1;155(7):3292-5
7561021
Annu Rev Immunol. 1994;12:593-633
8011292
Trends Biotechnol. 2002 Jan;20(1):9-12
11742671
Trends Immunol. 2002 Nov;23(11):541-8
12401407
Int Immunopharmacol. 2002 Jan;2(1):1-13
11789660
J Biol Chem. 1984 May 10;259(9):5430-9
6371005
Mol Pharmacol. 2007 Apr;71(4):1061-74
17229869
Mol Pharmacol. 2004 Nov;66(5):1213-22
15308762
Nat Methods. 2006 May;3(5):361-8
16628206
Mol Pharmacol. 2008 Aug;74(2):392-402
18458054
Int Immunol. 1993 Oct;5(10):1239-49
7505609
Proc Natl Acad Sci U S A. 1975 Mar;72(3):1059-62
1093163
J Neurosci. 2001 Jan 15;21(2):RC123
11160457
FASEB J. 2001 Nov;15(13):2454-62
11689470
Nat Biotechnol. 2002 Feb;20(2):155-62
11821861
J Biol Chem. 2001 Jun 29;276(26):23645-52
11316806
Mol Pharmacol. 2005 Nov;68(5):1301-10
16118363